BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Winrevair (Sotatercept) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Winrevair (Sotatercept)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01562405-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Winrevair (Sotatercept): Phase 1 readout est. (NCT01562405)
DESCRIPTION:Winrevair (Sotatercept)\, phase 1.\nStudy: Sotatercept (ACE-011
 ) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refracto
 ry Multiple Myeloma\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT01562405
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07356778-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Winrevair (Sotatercept): Phase 4 readout est. (NCT07356778)
DESCRIPTION:Winrevair (Sotatercept)\, phase 4\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Study of Sotatercept for Patients With Eisenmenger Syndrom
 e or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant
  to Vasodilator Therapy\nEstimated primary completion: 31 August 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07356778
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05825417-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Winrevair (Sotatercept): Phase 4 readout est. (NCT05825417)
DESCRIPTION:Winrevair (Sotatercept)\, phase 4\, Pulmonary Arterial Hyperten
 sion.\nStudy: Pulmonary Hypertension: Intensification and Personalisation 
 of Combination Rx\nEstimated primary completion: January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/sotatercept#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05825417
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357974-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Winrevair (Sotatercept): Phase 1/2 readout est. (NCT07357974)
DESCRIPTION:Winrevair (Sotatercept)\, phase 1/2\, Pulmonary Arterial Hypert
 ension.\nStudy: Impact of Sotatercept on Pulmonary Artery and Right Ventri
 cle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH
 \nEstimated primary completion: 1 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07357974
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899905-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Winrevair (Sotatercept): Phase 4 readout est. (NCT07899905)
DESCRIPTION:Winrevair (Sotatercept)\, phase 4\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of MK-7962 in Chinese Participants With Pul
 monary Arterial Hypertension (MK-7962-022)\nEstimated primary completion: 
 21 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotate
 rcept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07899905
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700303-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Winrevair (Sotatercept): Phase na readout est. (NCT07700303)
DESCRIPTION:Winrevair (Sotatercept)\, phase na\, Pulmonary Arterial Hyperte
 nsion.\nStudy: Withdrawal of Prostacyclin Pathway Therapy in Patients With
  Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)\nEstimat
 ed primary completion: 30 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07700303
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498803-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07498803)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: Sota-ES - Sotatercept in Patients With Congenital Heart Dise
 ase and Eisenmenger´s Syndrome\nEstimated primary completion: 31 March 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07498803
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600723-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280403
DTEND;VALUE=DATE:20280404
SUMMARY:Winrevair (Sotatercept): Phase 4 readout est. (NCT07600723)
DESCRIPTION:Winrevair (Sotatercept)\, phase 4\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Study of Sotatercept (MK-7962) in People With Pulmonary Ar
 terial Hypertension (PAH) in India (MK-7962-037)\nEstimated primary comple
 tion: 3 April 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 otatercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07600723
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925750-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06925750)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of Sotatercept (MK-7962) in People With Pul
 monary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)\nEstimated p
 rimary completion: 16 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06925750
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938294-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Winrevair (Sotatercept): Phase 4 readout est. (NCT07938294)
DESCRIPTION:Winrevair (Sotatercept)\, phase 4\, Pulmonary Arterial Hyperten
 sion.\nStudy: Sotatercept in the Treatment of Methamphetamine-Associated P
 ulmonary Arterial Hypertension\nEstimated primary completion: 1 September 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793829
 4
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05587712-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280921
DTEND;VALUE=DATE:20280922
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT05587712)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: Study to Evaluate Sotatercept (MK-7962) in Children With Pul
 monary Arterial Hypertension (PAH) (MK-7962-008)\nEstimated primary comple
 tion: 21 September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sotatercept#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05587712
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266519-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07266519)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: SIRIUS - Initial Combination Therapy With an Endothelin Rece
 ptor Antagonist\, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patie
 nts With Newly Diagnosed Pulmonary Arterial Hypertension\nEstimated primar
 y completion: October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sotatercept#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07266519
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218029-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Winrevair (Sotatercept): Phase 3 readout est. (NCT07218029)
DESCRIPTION:Winrevair (Sotatercept)\, phase 3\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Clinical Study of Sotatercept (MK-7962) in People With Pul
 monary Arterial Hypertension (MK-7962-038)\nEstimated primary completion: 
 7 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sota
 tercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07218029
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140484-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Winrevair (Sotatercept): Phase 4 readout est. (NCT07140484)
DESCRIPTION:Winrevair (Sotatercept)\, phase 4\, Pulmonary Arterial Hyperten
 sion.\nStudy: Sotatercept in Pulmonary Arterial Hypertension\nEstimated pr
 imary completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07140484
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351345-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20290204
DTEND;VALUE=DATE:20290205
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06351345)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: 129 Xenon Imaging in Patients Treated With Sotatercept\nEsti
 mated primary completion: 4 February 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06351345
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646860-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20290524
DTEND;VALUE=DATE:20290525
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT07646860)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2\, Pulmonary Arterial Hyperten
 sion.\nStudy: A Study of Sotatercept (MK-7962) in Japanese Children With P
 ulmonary Arterial Hypertension (PAH) (MK-7962-032)\nEstimated primary comp
 letion: 24 May 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sotatercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07646860
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839585-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20300108
DTEND;VALUE=DATE:20300109
SUMMARY:Winrevair (Sotatercept): Phase 3 readout est. (NCT07839585)
DESCRIPTION:Winrevair (Sotatercept)\, phase 3\, Heart Failure.\nStudy: A Cl
 inical Study of Sotatercept (MK-7962) in People With Combined Postcapillar
 y and Precapillary Pulmonary Hypertension and Heart Failure With Preserved
  Ejection Fraction (MK-7962-041)\nEstimated primary completion: 8 January 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sotatercept#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0783958
 5
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06814145-534@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20350810
DTEND;VALUE=DATE:20350811
SUMMARY:Winrevair (Sotatercept): Phase 2 readout est. (NCT06814145)
DESCRIPTION:Winrevair (Sotatercept)\, phase 2.\nStudy: Extension Study of S
 otatercept in People With Pulmonary Hypertension (MK-7962-023)\nEstimated 
 primary completion: 10 August 2035. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sotatercept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06814145
URL:https://assetmemo.bio/drug/sotatercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
